Drug Profile
Odalasvir - Achillion Pharmaceuticals
Alternative Names: ACH-0143102; ACH-3102; JNJ-64289901; ODVLatest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals
- Developer Achillion Pharmaceuticals; Alios BioPharma
- Class Antivirals; Benzimidazoles; Indoles; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 24 Feb 2021 Discontinued - Phase-I for Hepatitis C (Combination therapy, In volunteers) in France (PO) (Alexion Pharmaceuticals pipeline, February 2021)
- 24 Feb 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Moldova, Mauritius, United Kingdom, Japan (PO) (Alexion Pharmaceuticals pipeline, February 2021)